BridgeBio Pharma Inc (NAS:BBIO)
$ 27.94 0.18 (0.65%) Market Cap: 5.23 Bil Enterprise Value: 6.44 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 54/100

BridgeBio Pharma Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 14, 2020 / 03:00PM GMT
Release Date Price: $30.6 (-0.58%)
Gregory Allen Harrison
BofA Merrill Lynch, Research Division - Research Analyst

Hello, everyone. Welcome to the morning session of Day 3 of the Bank of America Virtual Vegas Healthcare Conference. I'm Greg Harrison, U.S. biopharma analyst here at BofA. And I'm very excited that we have BridgeBio here with us today. My colleague, Jason Zemansky, is on the line as well.

And here to speak on behalf of BridgeBio is CEO, Neil Kumar. The format is fireside chat. So feel free to send me questions, and I can ask them anonymously.

So Neil, let's jump right into the Q&A

Questions & Answers

Gregory Allen Harrison
BofA Merrill Lynch, Research Division - Research Analyst

Maybe you could just give us kind of an overview of your approach to development? And how your platform can potentially offer a higher probability of success in your programs?

Neil Kumar
BridgeBio Pharma, Inc. - Co-Founder, CEO & Director

Yes. Sure, happy to. Let me start by thanking you and the entire BAML team for the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot